Fluart Innovative Vaccine Ltd, Hungary
11
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
36%
4 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
Role: lead
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Role: lead
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
Role: lead
Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season
Role: lead
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
Role: lead
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
Role: lead
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
Role: lead
Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People
Role: lead
Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine
Role: lead
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons
Role: lead
Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine
Role: lead
All 11 trials loaded